If you went looking for homeopathic eye drops in a US pharmacy today, you would not find them. They are gone, pulled from shelves nationwide, along with every injectable homeopathic product once sold here. That disappearance was not a recall over contamination or a voluntary exit by manufacturers. It happened because federal regulators changed how they treat an entire category of medicine, and the rules that replaced the old approach left no clear way for many products to stay legally on the market.

The Homeopathic Drug Product Safety, Quality, and Transparency Act is the legislative response to that gap. Introduced in both chambers of Congress in 2026, the bill would write a dedicated set of rules for homeopathic medicines into federal law for the first time, rather than leaving the category to shifting enforcement decisions.

At The Relief Products, we have spent more than three decades manufacturing FDA-registered, over-the-counter homeopathic medicines inside this regulatory environment. We follow this legislation closely, and we support its goal of restoring clear, written rules for the category we work in every day. What follows is a plain-language overview of what the bill is, why it exists, what it would change, and how its supporters are working to pass it, written for the everyday product users who have found this a hard piece of legislation to make sense of.

What Is Homeopathic Medicine and How Has the FDA Regulated It?

Homeopathy is a system of medicine developed in the late 1700s built on two core ideas. The first is “like cures like,” the notion that a substance causing symptoms in a healthy person can, in a highly diluted form, address similar symptoms in someone who is unwell. The second is the law of minimum dose, the practice of diluting an active substance repeatedly so that very little of the original material remains in the finished product. According to the NIH’s National Center for Complementary and Integrative Health, these preparations are drawn from natural sources such as plants and minerals [1].

That formulary is the Homeopathic Pharmacopoeia of the United States, or HPUS, which has been in continuous publication since 1897. It defines the standards a substance must meet to be recognized as a homeopathic ingredient, and it sits at the center of how these medicines are regulated.

Homeopathic medicines have held a defined place in US law for a long time. When Congress passed the Federal Food, Drug, and Cosmetic Act in 1938, the legislation recognized the HPUS alongside the United States Pharmacopoeia as an official compendium of drugs. Senator Royal Copeland, a physician trained in homeopathy who helped author the Act, wrote that recognition directly into the law [2]. For roughly eight decades after that, the FDA managed homeopathic products through enforcement policy rather than statute, most notably under a 1988 document called Compliance Policy Guide 400.400. That guide laid out the conditions under which homeopathic drugs could be marketed.

In 2019, the FDA withdrew Compliance Policy Guide 400.400. Removing it left the category without the longstanding, FDA-accepted framework that manufacturers and regulators had relied on for years, and it set the stage for the changes that followed.

Why Congress Is Acting: The 2022 FDA Guidance and Its Impact

In December 2022, the FDA finalized new guidance for homeopathic drug products (Docket FDA-2017-D-6580, published at 87 Fed. Reg. 75054). The guidance described a risk-based enforcement approach that treats homeopathic medicines as unapproved new drugs marketed without the required FDA approval [3]. Because no homeopathic product has gone through the agency’s new-drug approval process, that classification effectively placed the entire category in a position of being subject to enforcement.

The practical consequences have already arrived. Entire product categories have disappeared from the US market under this approach, including all homeopathic eye drops and injectable homeopathic products [4]. For remaining products, the guidance offers a pathway for removal but no clear, codified route to stay legally on the market, which leaves manufacturers operating under ongoing enforcement uncertainty.

This is the category we work in. The 2022 category removal affected the kind of homeopathic eye care products that companies like ours have long made. We manufacture our products in FDA-registered facilities to current good manufacturing practice (CGMP) standards, as we have for more than three decades, which is why we track this legislation as closely as we do. The point here is not to argue against the FDA’s authority to police product safety. It is to explain why a bill aimed at restoring a clear, written framework has drawn support across the homeopathic manufacturing and practitioner community.

What Does the Bill Actually Do? Key Provisions

The bill amends the FDCA by adding a new section 503E that applies specifically to homeopathic drug products. Rather than subjecting them to the full drug-approval chapter of the law, the new section applies only the provisions on adulteration and misbranding plus product registration, and builds a category-appropriate framework around them. The table below summarizes the core provisions drawn from the full text of the House bill [5].

A few of these provisions deserve a closer look. The labeling requirement is one consumers would notice directly. Retail homeopathic products would be required to carry a specific statement on the package:

“These indications have not been evaluated by the Food and Drug Administration. This product is intended for traditional homeopathic uses.”

That language is meant to function as transparency, telling shoppers plainly how the product is regulated, rather than as a warning against use.

The Homeopathic Drug Product Advisory Committee is another notable piece. Under the House bill, it would seat ten members, including a consumer representative serving as chair, two manufacturer representatives, an HPCUS representative, a standards-body representative, an MD or DO trained in homeopathy, a naturopathic homeopath, a pharmacist or chemist, a veterinarian, and the FDA Commissioner. The committee would advise the agency on how the category is regulated.

The House and Senate versions share the same objectives but differ in detail. The Senate bill, S. 4692, is more streamlined and less prescriptive. It condenses the findings and definitions and leaves more of the implementation to future FDA rulemaking, while still aiming to recognize homeopathic medicines as a distinct category, exempt them from premarket approval, establish an advisory framework, and withdraw the 2022 guidance.

Where the Bill Stands: Current Status in Congress

Both bills are early in the legislative process and have not yet received a floor vote.

• H.R. 7050 was introduced in the House on January 14, 2026 by Representative Pete Sessions of Texas, with Representatives Mike Kennedy of Utah and Jonathan Jackson of Illinois as cosponsors. It was referred to the House Committee on Energy and Commerce [5].
• S. 4692 was introduced in the Senate on June 4, 2026 by Senators Tommy Tuberville of Alabama and Mike Lee of Utah, building what the sponsors describe as an FDA framework for homeopathic medicine [6].

The bill has drawn a broad coalition of supporters. The Senate sponsors’ announcement names Americans for Homeopathy Choice, MAHA Action, the CPAC Foundation, the National Health Federation, the Health Freedom Defense Fund, and the Natural Products Association among its endorsers [6], part of what backers describe as more than fifty national and state homeopathy organizations and advocacy groups [4]. Americans for Homeopathy Choice led a multi-year stakeholder process involving manufacturers and practitioners along with consumers before the bill was drafted. Whether either chamber advances the legislation remains to be seen, and we make no prediction here about its prospects.

How Supporters Are Working to Pass It

Getting a bill introduced is only the beginning. Americans for Homeopathy Choice, the consumer group that helped shepherd the legislation, describes it as the culmination of seven years of work, with the harder task of moving it through both chambers and to the president’s desk still ahead [7].

That push is largely grassroots. Supporters are organizing a volunteer Homeopathy Action Team designed to connect everyday advocates with their own members of Congress, and dozens of organizations across the homeopathy community have already signed its formal statement of support [7]. For readers who want to follow the bill’s progress or add their voice, Americans for Homeopathy Choice is coordinating the public campaign at homeopathychoice.org.

We are following it the same way many in this field are: as a company that makes these medicines and wants to see them governed by clear, durable rules. We are not telling anyone how to act on it. We are simply pointing to where the conversation is happening so you can decide for yourself how closely to follow.

A Widely Used Category That Deserves Clear Rules

Homeopathic medicines are part of daily life for a large number of American families. A 2012 National Health Interview Survey estimated that about 5 million adults and 1 million children in the US had used homeopathic medicines [1]. For all those households, the question the bill answers is a basic one: will these products remain available under a clear, predictable set of rules, or keep disappearing category by category under shifting enforcement?

Supporters frame the legislation as a matter of regulatory clarity and consumer access. It is not a claim about any individual product’s results. It is about giving a long-established category a written, homeopathic-appropriate framework instead of leaving it to guidance documents that can change overnight. Safety oversight stays firmly in place: federal adverse-event reporting standards for nonprescription drugs would continue to apply to homeopathic products under the bill.

This is the intersection we operate at. We manufacture to CGMP quality standards, register our products with the FDA, and we support clear, written regulation of the kind this bill proposes because it serves both the consumers who rely on these medicines and the responsible manufacturers who make them. Regulatory certainty makes it easier for shoppers to know what they are buying and for companies to meet a consistent standard.

What This Means for Homeopathic Medicine Users

If you use homeopathic products, the most useful question is a practical one: what would actually change, and what would stay the same?

What would change if the bill passes. Products that meet the bill’s standards would have a clear, codified path to remain on the market, rather than operating under enforcement uncertainty. The framework would be written into law instead of resting on guidance documents that can be revised. Retail packaging would carry the mandatory disclaimer described earlier, giving shoppers clearer information about how the product is regulated. And manufacturers would gain a defined, homeopathic-appropriate CGMP standard within three years of enactment.

What would stay the same. The FDA would keep its authority to act against products that are unsafe, adulterated, or misbranded. Adverse-event reporting would still apply. The bill does not remove federal oversight; it defines how that oversight works for this specific category.

What it means for reading a label. The new disclaimer is a transparency statement, not a warning. It tells you the product is intended for traditional homeopathic uses and that its indications have not been evaluated through the federal drug-approval process. It is information to help you make an informed choice, not a caution against the product itself.

For our part, this is already close to how we operate. We make FDA-registered, OTC homeopathic medicines with 100% natural active ingredients, manufactured to CGMP standards. You can see our full range on our shop page. This legislation would mainly provide written certainty for the category we have worked in for more than three decades.

Frequently Asked Questions

What is the Homeopathic Drug Product Safety, Quality, and Transparency Act? It is federal legislation, introduced as H.R. 7050 in the House and S. 4692 in the Senate, that would create a dedicated statutory framework for homeopathic drug products. It would recognize them as a distinct category, exempt them from premarket new-drug approval, set homeopathic-appropriate quality standards, and withdraw the FDA’s December 2022 guidance.

Why was the bill introduced? What problem does it solve? The December 2022 guidance treated all homeopathic medicines as unapproved new drugs without offering a clear path to stay legally on the market. Entire categories, including homeopathic eye drops and injectables, have already left US shelves. The bill aims to replace that uncertainty with clear, written rules for the category.

Does the bill change what homeopathic products can claim? The bill is about how these medicines are regulated, not a verdict on how well any individual product works. It does not change the core rule that homeopathic products are intended for traditional homeopathic uses as indicated on their labels. What it does is give the category clear, written standards and preserve consumer access, while keeping the FDA’s safety oversight in place.

Are homeopathic eye drops coming back to the market if this bill passes? The legislation would withdraw the 2022 guidance and create a framework under which compliant products could be marketed, but it does not automatically return any specific product to shelves. Whether a given homeopathic eye care product returns would depend on the manufacturer and on meeting the standards the bill and subsequent FDA rulemaking establish.

What is the HPUS and why does it matter for the bill? The HPUS, or Homeopathic Pharmacopoeia of the United States, is the official formulary defining standards for homeopathic ingredients. It has been published since 1897 and was recognized in federal law in 1938. The bill uses HPUS standards as the basis for measuring whether a homeopathic product is adulterated.

How does this bill affect The Relief Products specifically? We already manufacture to CGMP standards and register our products with the FDA, so our basic approach would not change. The main effect would be to give the homeopathic category we operate in a clear, written set of rules, which we believe benefits both consumers and responsible manufacturers.

References

[1] NCCIH / NIH. “Homeopathy.” National Center for Complementary and Integrative Health, April 2021. https://www.nccih.nih.gov/health/homeopathy

[2] Susan Beal, DVM. “H.R.7050 – A Bill to protect the future of Homeopathy for everyone.” Northeast Organic Dairy Producers Alliance, March 2026. https://nodpa.com/n/9240/HR7050-A-Bill-to-protect-the-future-of-Homeopathy-for-everyone

[3] FDA Center for Drug Evaluation and Research. “Homeopathic Drug Products Guidance for FDA Staff and Industry.” U.S. Food and Drug Administration, December 7, 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/homeopathic-drug-products-guidance-fda-staff-and-industry

[4] Americans for Homeopathy Choice. “Legislative Update.” homeopathychoice.org, June 10, 2026. https://homeopathychoice.org/legislative-update/

[5] U.S. Congress. “Text – H.R.7050 – 119th Congress (2025-2026): Homeopathic Drug Product Safety, Quality, and Transparency Act.” Congress.gov, January 14, 2026. https://www.congress.gov/bill/119th-congress/house-bill/7050/text

[6] Office of Senator Mike Lee. “Lee, Tuberville Introduce Protections for Homeopathic Medicine with FDA Marketing Pathway Framework.” U.S. Senate, June 5, 2026. https://www.lee.senate.gov/2026/6/lee-tuberville-introduce-protections-for-homeopathic-medicine-with-fda-approval-framework

[7] Americans for Homeopathy Choice. “How You Can Help Pass the Homeopathic Bill.” homeopathychoice.org, June 2026. https://homeopathychoice.org/how-you-can-help-pass-the-homeopathic-bill/